Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.

A cancer survivor celebrates being cancer-free, reflecting on her journey through breast cancer and treatments. The couple's ...

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.

I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.